FDA Nod for Merck HIV Drug Brings Competition to a Gilead Sciences Antiretroviral
Merck’s HIV drug Idvynso could become a drug choice for patients who need to switch from Gilead Sciences’ Biktarvy for safety or tolerability reasons. The Merck combination drug pa...